Stocks News

LAST PRICE
33.9300
TODAY'S CHANGE (%)
Trending Down-0.2100 (-0.6151%)

Bid / Lots
33.9300/ 2
Ask / Lots
34.0000/ 2
Open / Previous Close
34.1400 / 34.1400
Day Range
Low 33.7800
High 34.6900
52 Week Range
Low 24.3400
High 73.8000
Volume
1,134,980
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 27, 2024
- Apellis Pharmaceuticals to Present at Upcoming Investor Conferences, from 7:00AM ET on Wednesday Nov 27, 2024 by Dow Jones
  7:00AM ET on Wednesday Nov 27, 2024 by Dow Jones
  Companies Mentioned: APLS
  
  Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
  
  WALTHAM, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following December investor conferences:
Nov 21, 2024
- DJ Apellis Pharmaceuticals Initiated at Equal-Weight by Morgan Stanley, from 6:33AM ET on Thursday Nov 21, 2024 by Dow Jones
  6:33AM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: APLS
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/APLS/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 21, 2024 06:33 ET (11:33 GMT)
Nov 19, 2024
- DJ Apellis Pharmaceuticals Up Nearly 16%, On Pace for Largest Percent Increase Since August 2023 -- Data Talk, from 1:25PM ET on Tuesday Nov 19, 2024 by Dow Jones
  1:25PM ET on Tuesday Nov 19, 2024 by Dow Jones
  Companies Mentioned: APLS
  
  Apellis Pharmaceuticals, Inc. (APLS) is currently at $30.31, up $4.13 or 15.78%
  
  --Would be highest close since Sept. 25, 2024, when it closed at $30.59
  
  --On pace for largest percent increase since Aug. 23, 2023, when it rose 30.17%
Nov 12, 2024
- Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: APLS
  
  Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
  
  WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:30 a.m. GMT.
Nov 7, 2024
- DJ Apellis Pharmaceuticals Is Maintained at Outperform by Baird, from 12:51PM ET on Thursday Nov 07, 2024 by Dow Jones
  12:51PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: APLS
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/APLS/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 07, 2024 12:51 ET (17:51 GMT)

Nov 27, 2024
- B. Riley Raises Price Target on Denali Therapeutics to $38 From $33, Keeps Buy Rating, from 7:57AM ET on Wednesday Nov 27, 2024 by MT Newswires
  7:57AM ET on Wednesday Nov 27, 2024 by MT Newswires
  Companies Mentioned: DNLI
Nov 26, 2024
- Ultragenyx to Participate in Investor Conferences in December, from 4:30PM ET on Tuesday Nov 26, 2024 by Dow Jones
  4:30PM ET on Tuesday Nov 26, 2024 by Dow Jones
  Companies Mentioned: RARE
Nov 21, 2024
- DJ Ultragenyx Pharma Is Maintained at Overweight by JP Morgan, from 10:01AM ET on Thursday Nov 21, 2024 by Dow Jones
  10:01AM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: RARE
Nov 20, 2024
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), from 4:30PM ET on Wednesday Nov 20, 2024 by Dow Jones
  4:30PM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: RARE
Nov 18, 2024
- DJ Veracyte Is Maintained at Underweight by Morgan Stanley, from 10:41AM ET on Monday Nov 18, 2024 by Dow Jones
  10:41AM ET on Monday Nov 18, 2024 by Dow Jones
  Companies Mentioned: VCYT
- Morgan Stanley Lifts Price Target on Veracyte to $28 From $26, Keeps Underweight Rating, from 6:51AM ET on Monday Nov 18, 2024 by MT Newswires
  6:51AM ET on Monday Nov 18, 2024 by MT Newswires
  Companies Mentioned: VCYT
Nov 15, 2024
- Wolfe Research Initiates Veracyte at Outperform With $50 Price Target, from 7:34AM ET on Friday Nov 15, 2024 by MT Newswires
  7:34AM ET on Friday Nov 15, 2024 by MT Newswires
  Companies Mentioned: VCYT
Nov 14, 2024
- Veracyte Insider Sold Shares Worth $585,663, According to a Recent SEC Filing, from 4:45PM ET on Thursday Nov 14, 2024 by MT Newswires
  4:45PM ET on Thursday Nov 14, 2024 by MT Newswires
  Companies Mentioned: VCYT
- CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference, from 8:30AM ET on Thursday Nov 14, 2024 by Dow Jones
  8:30AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: CRSP
Nov 13, 2024
- Denali Therapeutics Insider Sold Shares Worth $1,932,665, According to a Recent SEC Filing, from 7:06PM ET on Wednesday Nov 13, 2024 by MT Newswires
  7:06PM ET on Wednesday Nov 13, 2024 by MT Newswires
  Companies Mentioned: DNLI

Apellis Pharmaceuticals Inc
NASDAQ:APLSUnited States

Search Criteria

Nov 27, 2024

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences, from 7:00AM ET on Wednesday Nov 27, 2024 by Dow Jones

Nov 21, 2024

DJ Apellis Pharmaceuticals Initiated at Equal-Weight by Morgan Stanley, from 6:33AM ET on Thursday Nov 21, 2024 by Dow Jones

Nov 19, 2024

DJ Apellis Pharmaceuticals Up Nearly 16%, On Pace for Largest Percent Increase Since August 2023 -- Data Talk, from 1:25PM ET on Tuesday Nov 19, 2024 by Dow Jones

Nov 12, 2024

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

Nov 7, 2024

DJ Apellis Pharmaceuticals Is Maintained at Outperform by Baird, from 12:51PM ET on Thursday Nov 07, 2024 by Dow Jones

Peers Headlines

Nov 27, 2024

B. Riley Raises Price Target on Denali Therapeutics to $38 From $33, Keeps Buy Rating, from 7:57AM ET on Wednesday Nov 27, 2024 by MT Newswires

Nov 26, 2024

Ultragenyx to Participate in Investor Conferences in December, from 4:30PM ET on Tuesday Nov 26, 2024 by Dow Jones

Nov 21, 2024

DJ Ultragenyx Pharma Is Maintained at Overweight by JP Morgan, from 10:01AM ET on Thursday Nov 21, 2024 by Dow Jones

Nov 20, 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), from 4:30PM ET on Wednesday Nov 20, 2024 by Dow Jones

Nov 18, 2024

DJ Veracyte Is Maintained at Underweight by Morgan Stanley, from 10:41AM ET on Monday Nov 18, 2024 by Dow Jones

Morgan Stanley Lifts Price Target on Veracyte to $28 From $26, Keeps Underweight Rating, from 6:51AM ET on Monday Nov 18, 2024 by MT Newswires

Nov 15, 2024

Wolfe Research Initiates Veracyte at Outperform With $50 Price Target, from 7:34AM ET on Friday Nov 15, 2024 by MT Newswires

Nov 14, 2024

Veracyte Insider Sold Shares Worth $585,663, According to a Recent SEC Filing, from 4:45PM ET on Thursday Nov 14, 2024 by MT Newswires

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference, from 8:30AM ET on Thursday Nov 14, 2024 by Dow Jones

Nov 13, 2024

Denali Therapeutics Insider Sold Shares Worth $1,932,665, According to a Recent SEC Filing, from 7:06PM ET on Wednesday Nov 13, 2024 by MT Newswires